Adiponectin as a Protective Factor Against the Progression Toward Type 2 Diabetes Mellitus in Postmenopausal Women.
Serum adiponectin levels have been suggested to be predictors of type 2 diabetes mellitus in diverse populations. However, the relationship between circulating adiponectin levels and the risk of development of type 2 diabetes in postmenopausal women has not been investigated.A total of 382 healthy postmenopausal women who participated in a prospective cohort study were followed for 5.8 years. Type 2 diabetes mellitus was defined according to the criteria set out by the American Diabetes Association. Adiponectin, osteoprotegerin (OPG), and high-sensitivity C-reactive protein (hs-CRP) levels were measured using ELISA.Of 195 women who did not have diabetes at baseline and who were reexamined in the second phase of the study for diabetic status, 35 subjects (17.9%) developed type 2 diabetes mellitus during the 5.8 years follow-up period. The women with type 2 diabetes had lower adiponectin levels than the healthy postmenopausal women. Multiple regression analysis showed that, after adjustments were made for age, cardiovascular risk factors, OPG, and hs-CRP levels, higher baseline adiponectin levels were associated with a lower relative risk (RR) of having type 2 (RR = 0.07, confidence interval [CI]: 0.01-0.66, P = 0.021).Higher baseline adiponectin levels functioned as a predictor of a lower risk of developing type 2 diabetes mellitus among postmenopausal women during a 5.8 years follow-up study. Therefore, it is suggested that elevated adiponectin levels may offer protection against the development of type 2 diabetes mellitus after the menopause.
From the Department of Endocrine Disorders, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran (HD, MRK, IN); Department of Infectious Diseases, The Persian Gulf Tropical Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran (AR, AO, KV); The Persian Gulf Nuclear Medicine Research Center, Bushehr University of Medical Sciences, Bushehr, Iran (MA); Department of Endocrinology and Metabolism, NYU Langone Medical Center, NYU, New York, USA (KA); Department on Internal Medicine, NYU Langone Medical Center, NYU, New York, USA (KA); and Department of Biochemistry, The Persian Gulf Marine Biotechnology Research Center, Bushehr University of Medical Sciences, Bushehr, Iran (SD).
Hossein
H
Darabi
Alireza
A
Raeisi
Mohammad Reza
MR
Kalantarhormozi
Afshin
A
Ostovar
Majid
M
Assadi
Kamyar
K
Asadipooya
Katayoun
K
Vahdat
Sina
S
Dobaradaran
Iraj
I
Nabipour
D052242:Adiponectin / Q000097:blood*; D002097:C-Reactive Protein / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology; D005260:Female; D006801:Humans; D007492:Iran / Q000453:epidemiology; D008875:Middle Aged; D053244:Osteoprotegerin / Q000097:blood; D017698:Postmenopause / Q000097:blood*; D065840:Protective Factors; D018570:Risk Assessment; D012307:Risk Factors
D052242:Adiponectin; D053244:Osteoprotegerin; D002097:C-Reactive Protein